Curis reports Q1 EPS ($2.05), consensus ($2.12)

Reports Q1 revenue $2.1M, consensus $2.4M. Curis’s cash, cash equivalents and investments totaled $40.7M as of March 31, and the Company had approximately 5.9M shares of common stock outstanding. Curis expects its existing cash, cash equivalents and investments will enable its planned operations into 2025. “We are very pleased to have several opportunities to present additional patient data in R/R AML patients with a targeted mutation, as well as progress updates for our R/R PCNSL and AML frontline triplet studies, at these prestigious oncology meetings,” said James Dentzer, President and CEO of Curis.